Cost-effectiveness of Daclatasvir in Combination with Sofosbuvir for the Treatment of Subjects with Genotype 3 Chronic Hepatitis C Infection in the United States

被引：0
|
作者：
Thibault, Catherine St-Laurent [1 ]
Moorjaney, Divya [1 ]
Ganz, Michael [1 ]
Sill, Bruce E. [2 ]
Hede, Shalini [2 ]
Yuan, Yong [2 ]
Kalsekar, Anupama [2 ]
Gorsh, Boris [2 ]
机构：
[1] Evidera, Modeling & Simulat, St Laurent, PQ, Canada
[2] Bristol Myers Squibb Co, Plainsboro, NJ USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1461
引用
收藏
页码：923A / 923A
页数：1
相关论文
共 50 条
  • [21] Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients
    Abdelaty, Lamiaa N.
    Elnaggar, Ahmed A.
    Said, Amira A.
    Hussein, Raghda R. S.
    CURRENT DRUG SAFETY, 2020, 15 (01) : 53 - 60
  • [22] Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
    Leleu, H.
    Blachier, M.
    Rosa, I.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (04) : 376 - 383
  • [23] Cost-effectiveness of elbasvir/grazoprevir plus sofosbuvir for the treatment of chronic HCV genotype 3 infection in Argentina
    Bissio, E.
    Nwankwo, C.
    Corman, S.
    Monsanto, H.
    Montes, J. L.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S189 - S190
  • [24] ESTIMATING THE COST-EFFECTIVENESS OF DACLATASVIR PLUS SOFOSBUVIR IN TREATMENT-NAIVE, TREATMENT-EXPERIENCED AND INTERFERON-INELIGIBLE/INTOLERANT PATIENTS WITH ADVANCED CHRONIC HEPATITIS C GENOTYPE 1 INFECTION
    McEwan, P.
    Webster, S.
    Ward, T.
    Kalsekar, A.
    Yuan, Y.
    Brenner, M.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S627 - S628
  • [25] The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States
    Eckman, Mark H.
    Kaiser, Tiffany E.
    Sherman, Kenneth E.
    CLINICAL INFECTIOUS DISEASES, 2011, 52 (11) : 1294 - 1306
  • [26] Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1
    Ciaccio, Antonio
    Cortesi, Paolo
    Bellelli, Giuseppe
    Rota, Matteo
    Rota, Monica
    Mantovani, Lorenzo G.
    Annoni, Giorgio
    Strazzabosco, Mario
    HEPATOLOGY, 2015, 62 : 919A - 919A
  • [27] Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C infected patients in the UK
    Cure, Sandrine
    Guerra, Ines
    Dusheiko, Geoffrey M.
    HEPATOLOGY, 2014, 60 : 660A - 660A
  • [28] Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients
    Cure, S.
    Guerra, I.
    Dusheiko, G.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (11) : 882 - 889
  • [29] COST-EFFECTIVENESS ANALYSIS OF SOFOSBUVIR FOR GENOTYPE 2 HEPATITIS C IN GREECE
    Athanasakis, K.
    Boubouchairopoulou, N.
    Kyriopoulos, I
    Tsoulas, C.
    Tzanakis, B.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2016, 19 (07) : A415 - A415
  • [30] Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results
    Gandjour, Afschin
    PLOS ONE, 2020, 15 (10):
12345